Please assess the completion status of the following clinical trial:

Trial Title: A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients must meet the following criteria for study entry:~* Histologically confirmed NSCLC~* Availability of a tumor specimen~* Recurrent or progressive disease following at least one chemo containing regimen for Stage IIIB/IV disease~* Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)~* At least one measurable lesion on a pre-treatment 18-fluorodeoxyglcose-positron emission tomography (FDG-PET) scan that is also a target lesion on computed tomography (CT) according to RECIST~Exclusion Criteria:~* More than two prior treatments for Stage IIIB/IV~* More than 30 days of exposure to an investigational or marketed agent that can act by EGFR inhibition, or a known epidermal growth factor receptor (EGFR)-related toxicity resulting in dose modifications~* Chemotherapy, biologic therapy, radiotherapy or investigational drug within 28 days prior to randomization~* Untreated and/or active (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) central nervous system (CNS) metastasis~* History of serious systemic disease within the past 6 months prior to randomization~* Uncontrolled diabetes~* Major surgical procedure or significant traumatic injury within 28 days prior to randomization~* Anticipation of need for a major surgical procedure during the course of the study~* Local palliative radiotherapy within 7 days prior to randomization or persistent adverse effects from radiotherapy that have not been resolved to Grade II or less prior to randomization~* Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MetMAb + Erlotinib (Type: EXPERIMENTAL): MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity.
- Placebo + Erlotinib (Type: PLACEBO_COMPARATOR): Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).